Recruitment

Recruitment Status
Completed
Estimated Enrollment
80

Inclusion Criteria

2nd line treatment for metastatic disease
Adjuvant treatment
Patient must be able to give own signed informed consent.
...
2nd line treatment for metastatic disease
Adjuvant treatment
Patient must be able to give own signed informed consent.
1st line treatment for metastatic disease
BRAF and/or MEK inhibitors
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients ≥ 18 years of age.
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Patients with prior adjuvant treatment are allowed.
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)

Summary

Conditions
  • Advanced Melanoma
  • Metastatic Melanoma
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

2nd line treatment for metastatic disease
Adjuvant treatment
Patient must be able to give own signed informed consent.
...
2nd line treatment for metastatic disease
Adjuvant treatment
Patient must be able to give own signed informed consent.
1st line treatment for metastatic disease
BRAF and/or MEK inhibitors
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patients ≥ 18 years of age.
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Patients with prior adjuvant treatment are allowed.
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)

Tracking Information

NCT #
NCT02177110
Collaborators
Not Provided
Investigators
Not Provided
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024